Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s
health innovation, today announced its participation in DTC
Perspectives’ Xpectives.Health Summit being held in Boston, MA from
October 12 – 14, 2021, at The Westin Copley Place.
“I’m excited to be part of an esteemed panel of
women to discuss the commitment and participation of the pharma
industry and investors in advancing women’s health innovation,”
said Sabrina Martucci Johnson, Daré’s President and CEO. “Daré is a
company developing a portfolio of novel candidates that address
persistent unmet needs for women, and we are deeply committed to
driving innovation in women’s health. The financial, development
and commercial support of other key industry participants remains
an important part of our strategy.”
Panel Details: |
|
|
|
|
|
Event: |
|
The Xpectives.Health Summit Women’s Health Conference |
|
|
|
Panel: |
|
Industry and Investors Commitment to Women’s Health |
|
|
|
Date: |
|
Thursday, October 14, 2021 |
|
|
|
Time: |
|
2:00 – 2:45 pm ET |
|
|
|
Moderator: |
|
Cheryl Kerr, Senior Director, Women’s Healthcare, Strategy and
Portfolio Management, Bayer Women’s Health |
|
|
|
Additional information about the event is
available at:
https://xpectives.health/xpectives-health-summit/.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
novel, hormone-free, monthly contraceptive
whose U.S. commercial rights are under a license
agreement with Bayer; Sildenafil Cream, 3.6%, a proprietary cream
formulation of sildenafil to treat female sexual arousal disorder
utilizing the active ingredient in Viagra®; DARE-BV1, a unique
hydrogel formulation of clindamycin phosphate 2% to treat bacterial
vaginosis via a single application; and DARE-HRT1, a combination
bio-identical estradiol and progesterone intravaginal ring for
hormone therapy following menopause. To learn more about Daré’s
full portfolio of women’s health product candidates, and mission to
deliver differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use these
channels to distribute material information about the company, and
may also use social media to communicate important information
about the company, its finances, product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted on
the investor relations page of Daré’s website mentioned above.
Forward-Looking Statements
Daré cautions you that all statements, other
than statements of historical facts, contained in this press
release, are forward-looking statements. Forward-looking
statements, in some cases, can be identified by terms such as
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“design,” “intend,” “expect,” “could,” “plan,” “potential,”
“predict,” “seek,” “should,” “would,” “contemplate,” “project,”
“target,” “tend to,” or the negative version of these words and
similar expressions. In this press release, forward-looking
statements include, but are not limited to, statements regarding
the potential for Daré to bring to market products that address
persistent unmet needs for women and Daré’s strategy.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Daré’s actual
results, performance or achievements to be materially different
from future results, performance or achievements expressed or
implied by the forward-looking statements in this press release,
including, without limitation, risk and uncertainties related to:
the risk that the FDA, other regulatory authorities or members of
the scientific or medical communities may not accept or agree with
Daré’s interpretation of or conclusions regarding the data from the
DARE-BVFREE clinical study and/or may require additional clinical
or nonclinical studies of DARE-BV1 prior to approving the NDA;
whether and when the NDA for DARE-BV1 pending with the FDA may be
approved and, if approved, whether DARE-BV1 will be commercially
successful; decisions by the FDA impacting labeling, manufacturing
processes, safety and/or other matters that could affect the
availability or commercial potential of DARE-BV1; Daré’s failure to
timely establish or leverage third-party partnerships or
collaborations to commercialize its product candidates, if
approved; Daré’s ability to raise additional capital when and as
needed to advance its product candidates and continue as a going
concern; the effects of the COVID-19 pandemic on Daré’s operations,
financial results and condition, and ability to achieve current
plans and objectives, including the potential impact of the
pandemic on Daré’s ability to timely enroll, conduct and report
results of its clinical trials and on the ability of third parties
on which Daré relies to assist in the conduct of its business,
including its clinical trials, to fulfill their contractual
obligations to Daré; Daré’s ability to develop, obtain regulatory
approval for, and commercialize its product candidates; the failure
or delay in starting, conducting and completing clinical trials or
obtaining FDA or foreign regulatory approval for Daré’s product
candidates in a timely manner; Daré’s ability to design and conduct
successful clinical trials, to enroll a sufficient number of
patients, to meet established clinical endpoints, to avoid
undesirable side effects and other safety concerns, and to
demonstrate sufficient safety and efficacy of its product
candidates; the risk that positive findings in early clinical
and/or nonclinical studies of a product candidate may not be
predictive of success in subsequent clinical and/or nonclinical
studies of that candidate; the risk that developments by
competitors make Daré’s product candidates less competitive or
obsolete; failure of Daré’s product candidates, if approved, to
gain market acceptance or obtain adequate coverage from third-party
payers; Daré’s ability to retain its licensed rights to develop and
commercialize a product candidate; Daré’s ability to satisfy the
monetary obligations and other requirements in connection with its
exclusive, in-license agreements covering the critical patents and
related intellectual property related to its product candidates;
Daré’s dependence on third parties to conduct clinical trials and
manufacture clinical trial material; the risks that the license
agreement with Bayer may not become effective and, if it becomes
effective, that future payments to Daré under the agreement may be
significantly less than the anticipated or potential amounts;
Daré’s ability to adequately protect or enforce its, or its
licensor’s, intellectual property rights; the lack of patent
protection for the active ingredients in certain of Daré’s product
candidates which could expose its products to competition from
other formulations using the same active ingredients; cyber
attacks, security breaches or similar events that compromise Daré’s
technology systems or those of third parties on which it relies
and/or significantly disrupt Daré’s business; and disputes or other
developments concerning Daré’s intellectual property rights. Daré’s
forward-looking statements are based upon its current expectations
and involve assumptions that may never materialize or may prove to
be incorrect. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. For a
detailed description of Daré’s risks and uncertainties, you are
encouraged to review its documents filed with
the SEC including Daré’s recent filings on Form 8-K, Form
10-K and Form 10-Q. You are cautioned not to place undue reliance
on forward-looking statements, which speak only as of the date on
which they were made. Daré undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
Contacts:
Investors on behalf of Daré Bioscience,
Inc.:Lisa Walters-Hoffert, Chief Financial OfficerDaré Bioscience,
Inc.lwalters@darebioscience.com 858.926.7655
OR
Media on behalf of Daré Bioscience, Inc.:Jake RobisonCanale
Communicationsjake.robison@canalecomm.com 619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024